REFERENCES


MRI in assessment of lung cancer

We congratulate Fischer et al for their significant and well-written article, published in this issue of Thorax.1 The report covers important topics in the imaging of lung cancer staging. The authors report that positron emission tomography (PET)-CT improves discrimination in metastatic disease. They also demonstrated that patients with enlarged lymph nodes on CT require confirmation independent of PET findings, and that a positive PET-CT finding requires confirmation before making a decision about surgery. We would, however, like to discuss and highlight an alternative technique with benefits for lung cancer staging.

Recent advancements in MRI systems (such as improved pulse sequences, utilisation of contrast media and new techniques such as diffusion) have made MRI an increasingly important tool for lung cancer staging. Reports have indicated the ability of MRI to reveal mediastinal tumour invasion and to help identify hilar and mediastinal nodal metastases.2–4 A series of 15 consecutive non-small cell lung carcinoma patients prospectively underwent CT, MRI and 18F-fluorodeoxyglucose (FDG)-PET, as well as surgical and pathological examinations. The study reported that the quantitative sensitivity (90.1%) and accuracy (92.2%) of MRI were significantly higher than the quantitative and qualitative sensitivities (76.7% and 74.4%) and accuracies (83.5% and 82.6%) of co-registered FDG-PET/CT on a per patient basis (p<0.05).4

The cost of imaging studies is an important consideration. The nature and complexity of the imaging system and the requirement for continuous production of radiopharmaceutical products makes PET/CT intrinsically more expensive than other imaging methods. The characteristics of MRI make it a safer modality than PET/CT. Unlike the ionising radiation used in CT, the powerful magnetic field and radiofrequency energy used in MRI have not been shown to cause cancer or fetal abnormalities. It is important to note that although x-rays are known to cause cancer, the exact risk of developing cancer from CT scans or repeated CT examinations is unknown.5 We hope that this short comment may encourage investigators to use and study MRI as a new method that offers considerable benefits for lung cancer staging.

Bruno Hochhegger,1 Edson Marchiori,2 Klaus Itron,3 Jose Moreira,1 Glaucia Zanetti2

1Department of Radiology, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil; 2Department of Radiology, Federal University of Rio de Janeiro, Petrópolis, Brazil; 3Department of Radiology, Liverpool Heart and Chest Hospitals, Liverpool, UK

Correspondence to Bruno Hochhegger, Santa Casa de Misericórdia de Porto Alegre, Rua Julo Alfredo 558/301, Porto Alegre, Brazil; brunohochhegger@gmail.com

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 11 January 2011
Published Online First 10 February 2011

REFERENCES


Risk disclosure prior to bronchoscopy

We read with interest the article by Uzbeck et al demonstrating increased patient anxiety upon receiving detailed information regarding complications of bronchoscopy; in addition to the letter by Echavarria et al documenting the consent practices of 33 respiratory physicians in the north east of England. A wide variation in practice is identified. The General Medical Council guidance for doctors relating to consent indicates that a physician ‘must tell patients if an investigation… might result in a serious adverse outcome, even if the likelihood is very small’. An adverse outcome is defined as one ‘resulting in death, permanent or long term physical disability or disfigurement, medium or long term pain, or admission to hospital’. The guidance also indicates that less serious side-effects or complications should be communicated if they occur frequently.

In reviewing the Uzbeck paper and their local practice, Echavarria et al2 feel that the appropriate balance between the disclosure of relevant risks and patient anxiety is one in which a high risk disclosure is advisable. However, it can be argued that this balance can only be struck in the knowledge of local and even personal bronchoscopic practice and performance, and that it is unethical to advise patients of risks that are neither serious nor common.

Many hospitals now utilise computer software to record and analyse bronchoscopy findings and outcomes. These software packages frequently allow the recording of relevant complications or side-effects with free text areas for the documentation of less frequently encountered, but clinically relevant, events. In a review of 1261 fibre-optic bronchosopies, recorded on InfoFlex 2 software (CIMS, Hertfordshire, UK) at Sheffield Teaching Hospitals NHS Foundation Trust over a 24-month period (1 December 2007 to 1 December 2009) 86.5% of patients did not encounter complications of sufficient severity for a record to be created. Data were unavailable for 4.2% of patients; 9.4% had documented bleeding and 2% were noted to have undergone desaturation requiring premature termination of the procedure or considered to be clinically relevant or unexpected. This latter group included those developing pneumothorax following transbronchial biopsy. No deaths were encountered in the patient cohort despite approximately 10% of the patient group undergoing interventional bronchoscopic procedures including laser therapy or stenting.

The quality of statistical output from any database is dependent on the quality of data entry and the consistency between clinicians in identifying and recording relevant complications. For instance, two clinicians may differ in their assessment of a ‘clinically relevant’ desaturation or bleeding event, and may therefore enter different datasets for a similar clinical experience, thus confounding analysis. However, for major complications, such as inaproopradural death or large volume haemorrhage, this is less likely to occur.

Our data would suggest that, in an appropriately selected patient group, administered to by experienced medical staff with appropriate training and expertise, major risks for bronchoscopy are infrequent and rarely life-threatening. On this basis the more limited information disclosure outlined by Uzbeck et al, with resultant lower levels of anxiety for patients may be more appropriate.

Stephen M Bianchi, Shironjit Saha, Paul Anderson
Northern General Hospital, Sheffield, UK
Correspondence to Dr Stephen M Bianchi, Chest Clinic, Northern General Hospital, Sheffield S5 7AU, UK; stephen.bianchi@sth.nhs.uk

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 4 September 2010
Published Online First 30 October 2010

REFERENCES